Drugs / SHR9146
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03491631 | Nov 2018 → Jun 2023 | metastatic malignant neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR9146 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03491631 ↗ |
| Action | Inhibit | “IDO1 inhibitor SHR9146” NCT03491631 ↗ |
| Target | IDO1 | “IDO1 inhibitor SHR9146” NCT03491631 ↗ |